Last reviewed · How we verify
Granata Bio Corporation — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| hMG subcutaneous injection | hMG subcutaneous injection | phase 3 | Growth hormone | Growth hormone receptor | Endocrinology |
Therapeutic area mix
- Endocrinology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Changchun GeneScience Pharmaceutical Co., Ltd. · 1 shared drug class
- Merck KGaA, Darmstadt, Germany · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Granata Bio Corporation:
- Granata Bio Corporation pipeline updates — RSS
- Granata Bio Corporation pipeline updates — Atom
- Granata Bio Corporation pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Granata Bio Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/granata-bio-corporation. Accessed 2026-05-16.